Ubs Group Ag Karyopharm Therapeutics Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 134,478 shares of KPTI stock, worth $94,134. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134,478

Previous 140,678 4.41%

Holding current value

$94,134

Previous $122,000 9.02%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.7 - $1.06 $4,340 - $6,572	-6,200 Reduced 4.41%	134,478 $111,000
Q2 2024 Aug 13, 2024	SELL	$0.87 - $1.58 $99,401 - $180,522	-114,255 Reduced 44.82%	140,678 $122,000
Q1 2024 May 13, 2024	SELL	$0.72 - $1.66 $145,621 - $335,738	-202,252 Reduced 44.24%	254,933 $384,000
Q4 2023 Feb 09, 2024	SELL	$0.68 - $1.31 $305,632 - $588,792	-449,460 Reduced 49.57%	457,185 $393,000
Q3 2023 Nov 09, 2023	BUY	$1.14 - $1.81 $534,699 - $848,953	469,035 Added 107.18%	906,645 $1.21 Million
Q2 2023 Aug 11, 2023	BUY	$1.79 - $4.59 $492,552 - $1.26 Million	275,169 Added 169.4%	437,610 $783,000
Q1 2023 May 12, 2023	SELL	$2.84 - $3.92 $1.02 Million - $1.41 Million	-360,818 Reduced 68.96%	162,441 $631,000
Q4 2022 Feb 08, 2023	BUY	$2.48 - $5.93 $1.02 Million - $2.44 Million	410,713 Added 364.93%	523,259 $1.78 Million
Q3 2022 Nov 10, 2022	SELL	$4.08 - $5.82 $836,355 - $1.19 Million	-204,989 Reduced 64.56%	112,546 $614,000
Q2 2022 Aug 10, 2022	SELL	$4.15 - $8.37 $833,838 - $1.68 Million	-200,925 Reduced 38.75%	317,535 $1.43 Million
Q1 2022 May 16, 2022	BUY	$5.91 - $14.38 $1.49 Million - $3.62 Million	251,465 Added 94.18%	518,460 $3.82 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $8.61 $1.78 Million - $2.94 Million	-341,490 Reduced 56.12%	266,995 $1.72 Million
Q3 2021 Nov 15, 2021	BUY	$4.45 - $10.63 $1.4 Million - $3.35 Million	314,950 Added 107.3%	608,485 $3.54 Million
Q2 2021 Aug 13, 2021	BUY	$8.11 - $11.11 $1.2 Million - $1.64 Million	147,514 Added 101.02%	293,535 $3.03 Million
Q1 2021 May 12, 2021	BUY	$9.85 - $17.69 $760,784 - $1.37 Million	77,237 Added 112.29%	146,021 $1.54 Million
Q4 2020 Feb 11, 2021	SELL	$14.15 - $17.19 $1.91 Million - $2.32 Million	-134,835 Reduced 66.22%	68,784 $1.07 Million
Q3 2020 Nov 12, 2020	BUY	$14.14 - $19.71 $979,916 - $1.37 Million	69,301 Added 51.59%	203,619 $2.97 Million
Q2 2020 Jul 31, 2020	BUY	$16.6 - $25.25 $2.11 Million - $3.21 Million	127,002 Added 1735.95%	134,318 $2.54 Million
Q1 2020 May 01, 2020	SELL	$14.38 - $27.72 $115,327 - $222,314	-8,020 Reduced 52.3%	7,316 $141,000
Q4 2019 Feb 14, 2020	SELL	$9.23 - $19.67 $1.74 Million - $3.71 Million	-188,406 Reduced 92.47%	15,336 $294,000
Q3 2019 Nov 14, 2019	BUY	$5.66 - $11.85 $1.14 Million - $2.38 Million	201,022 Added 7390.51%	203,742 $1.96 Million
Q1 2019 May 14, 2019	SELL	$4.12 - $10.25 $881,811 - $2.19 Million	-214,032 Reduced 98.75%	2,720 $16,000
Q4 2018 Feb 14, 2019	BUY	$8.2 - $16.95 $1.66 Million - $3.43 Million	202,455 Added 1416.07%	216,752 $2.03 Million
Q3 2018 Nov 14, 2018	BUY	$17.03 - $21.18 $80,551 - $100,181	4,730 Added 49.44%	14,297 $243,000
Q2 2018 Aug 14, 2018	SELL	$12.0 - $19.88 $120,780 - $200,092	-10,065 Reduced 51.27%	9,567 $163,000
Q1 2018 May 15, 2018	BUY	$9.92 - $17.25 $172,151 - $299,356	17,354 Added 761.81%	19,632 $264,000
Q4 2017 Feb 14, 2018	SELL	$9.15 - $11.99 $101,327 - $132,777	-11,074 Reduced 82.94%	2,278 $21,000
Q3 2017 Nov 14, 2017	BUY	$8.15 - $11.16 $78,900 - $108,039	9,681 Added 263.72%	13,352 $147,000
Q2 2017 Aug 14, 2017	BUY	N/A	2,276 Added 163.15%	3,671 $33,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,395	1,395 $18,000

Others Institutions Holding KPTI

# of Institutions

Shares Held

57.6M

Call Options Held

258K

Put Options Held

81.2K

View Full List

About Karyopharm Therapeutics Inc.

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $55.9M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

More about KPTI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account